Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
New deal strengthens Congenica’s presence in India
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Subscribe To Our Newsletter & Stay Updated
